GLPwatch
Two cases of type 2 diabetes mellitus in elderly patients successfully treated with monthly exenatide long-acting release.
Clin Case Rep · 2019
Last updated 2026-08-28| Journal | Clin Case Rep, 2019 |
|---|---|
| Citations | 3 |
| Relative citation ratio | 0.12 |
| NIH percentile | 8 |
| Molecules | exenatide |
Abstract
Two elderly patients with poorly controlled type 2 diabetes mellitus had difficulty self-managing their medications. Exenatide long-acting release (LAR), with an extended administration interval of 1 month, maintained hemoglobin A1c (HbA1c) level in the 7% range. Monthly administration of exenatide-LAR may be considered for use in carefully selected elderly individuals.
Verbatim abstract via PubMed 31110729 ↗
Related research
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
- Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
- Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
- Exenatide and the treatment of patients with Parkinson's disease.
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.
- Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.